Immunotherapy for allergic reactions

Acta Clinica Belgica

Volumn 53, Issue 2, 1998, Pages 66-72

  Stevens, W J ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ASTHMA; DESENSITIZATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; FOOD ALLERGY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INHALATIONAL DRUG ADMINISTRATION; INSECT ALLERGY; PATHOPHYSIOLOGY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; URTICARIA;

EID: 0031778138     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.1998.11754145     Document Type: Review

References (73)

1. Sanford A, Weir T, Paré P. The genetics of asthma. Am J Respir Crit Care Med. 1996; 153: 1749-65.
2. Warner JA, Jones AC, Miles EA, Colwell BM, Warner JO. Maternofetal interaction and allergy. Allergy. 1996; 51: 447-51.
3. Stevens WJ, Vermeire PA. Bronchial responsiveness to histamine and allergen in patients suffering from asthma, rhinitis, cough. Eur J Resp Dis. 1980; 61:203-12.
4. Curtis H. The immunizing cure for hay fever. N Y Med J. 1900, 74, 16.
5. Noon L. Profylactic inoculation against hay fever. Lancet. 1911, ii 1572-73.
6. CSM Update. Desensitising vaccines, Brit Med J. 1986; 293: 948.
7. International Union of Immunological Societies Working Group. Current status of allergen immunotherapy. Lancet. 1989; 259-61.
8. Mailing HJ. Immunotherapy, EAACI position paper. Allergy. 1988; 43: suppl 6, 1-33.
9. Bonifazi F, Bilo MB. Efficacy of specific immunotherapy in allergic asthma. Myth or reality? Allergy. 1997; 52: 698-710.
10. Bousquet J, Michel F.B. Specific immunotherapy in ashtma: is it effective? J Allergy Clin Immunol. 1994; 94: 1-11.
11. Oisen OT, Larsen KR, Jacobsen L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy. 1997: 52: 853-9.
12. Adkinson NF, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. New Eng J Med. 1997; 336: 324-31.
13. American Academy of Allergy, Asthma and Immunology. The use of standardized allergen extracts. J Allergy Clin Immunol. 1997; 99: 583-6.
14. Stevens W, Verhelst JA, van den Bogaert W, Bridts CH. Clinical and biological evaluation of semi-rush and ordinary immunotherapy schemes in type 1 allergic respiratory diseases. Allergy. 1985; 40: 447-52.
15. Hejjaoui A, Hammami M, Brociek WS, Dhivert H, Michel FB. Bousquet J. Protocole de désensibilisation accélérée aux pneumallergenes. Bilan d'un an de traitement. Rev Fr Allergol. 1985; 25: 29-33.
16. Andri L, Senna G, Betteli C et al. Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol. 1996; 97: 34-41.
17. Crimi E, Voltolini S, Troise C et al. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Immunol. 1991; 87: 721-8.
18. Litwin A, Flanagan M, Entis G et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol. 1997; 100: 30-8.
19. Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhiniconjunctivitis. J Allergy Clin Immunol. 1990; 85: 606-11.
20. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitization in children. J Allergy Clin Immunol. 1997; 99: 450-3.
21. Stevens WJ, Van Bever HP. Frequency and intensity of late asthmatic reactions after bronchial allergen challenge in asthma and rhinitis. Allergy. 1989; 44: 471-6.
22. Van Bever HP, Bosmans J, De Clerck LS, Stevens W. Modification of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus) or grass pollen. Allergy. 1988; 43: 378-85.
23. Van Bever HP, Stevens WJ. Suppression of the late asthmatic reaction by hyposensitization in asthmatic allergic to house dust mite (Dermatophagoides pteronyssinus). Clin Exp Allergy. 1989; 119: 399-404.
24. Van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatogoides pteronyssinus). Eur Respir J. 1992; 5: 318-22
25. Van Bever HP, Bridts CH, Moens MM et al. Lymphocyte transformation test with house dust mite (Dermatophagoides pteronyssinus) in normal children, asthmatic children and asthmatic children receiving hyposensitization. Clin Exp Allergy. 1993; 23: 661-8.
26. Nish WA, Charlesworth EN, Davis TL et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol. 1994; 93: 484-93.
27. Suko M, Mori A, Ito K, Okudaira H. Oral imunotherapy may induce T cell anergy. Int Arch Allergy Immunol. 1995; 107: 278-81.
28. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986; 1136: 2348-57.
29. Bonno M, Fujisawa T, Iguchi K et al. Mite-specific induction of interleukin-2 receptor on T lymphocytes from children with mite-sensitive asthma: modified immune response with immunotherapy. J Allergy Clin Immunol. 1996; 97: 680-8.
30. Ito H, Suzuki M, Mamiya S, Takagi L, Baba S. Study on changes in the level of serum IL-4 and soluble CD 23(s-CID23) with immunotherapy in nasal allergy patients. Acta Otolaryngol. 1996;S525: 98-104.
31. Zenner HP, Baumgarten C, Fuchs T et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol. 1997; 100: 23-9.
32. Van Bever HP, Stevens WJ. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. J Allergy Clin Immunol. 1990; 86: 141-6.
33. Creticos PS, Reed CE, Norman PS et al. Ragweed immunotherapy in adult asthma. N Eng J Med. 1996; 334: 501-6.
34. Poulsen LK, Lundberg L, Sondergaard I, Weeke B. Allergen-containing immune complexes used for immunotherapy of allergic asthma. Allergy. 1991; 46: 292-303.
35. Poulsen LK, Sondergaard I, Weeke B. Improvement of specific immunotherapy by human IgG and modified allergens. Allergy. 1989; 44: 241-55.
36. Machiels JJ, Buche M, Somville MA, Jacquemin MG, Saint-Remy JMR. Complexes of grass pollen allergens and specific antibodies reduce allergic symptoms and inhibit the seasonal increase of IgE antibody. Clin Exp Allergy. 1990; 20: 653-60.
37. Machiels JJ, Somville MA, Jacquemin MG, Saint-Remy JMR. Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergy. 1991:46: 335-48.
38. Saint-Remy JMR, Machiels, JJ. Allergen-antibody complexes in the treatment of Dermatophagoides pleronyssinus hypersensitivity diseases. Clin Exp Allergy. 1994. 124: 1091-3.
39. Mohapatra SS, Mohapatra S. Application of molecular biology for diagnosis and treatment of allergic diseases. Immunol Allergy Clin N Am. 1996; 16: 591-611.
40. Zhang L. Kisil FT, Sehon A, Mohapatra SS. Allergenic and antigenic cross-reactivities of group IX grass pollen ALs. Int Arch Allergy Appl Immunol. 1991; 96: 28.
41. Schou C. Allergens in rhinitis. B- and T-cell epitopes of allergen molecules. Clin Exp Allergy. 1995; 25: 10-14.
42. Briner T, Kuo M-C, Keating KM et al. Peripheral T cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat Al Fed d I. Proc Natl Acad Sci USA. 1993.190: 7608.
43. Hoyne GF, O'Hehir RE, Wraith DC et al. Inhibition of T cell and antibody responses to house dust mite allergens by inhalations of the dominant T cell epitopes in naive and sensitized mice. J Exp Med. 1993; 178: 1783-8.
44. Norman PS, Ohman JL, Long AA et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996; 154: 1623-8.
45. Danzig M, Cuss F. Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation. Allergy. 1997; 52: 787-94.
46. Reisman RE, Dvorin DJ, Randolph CC, Georgitis JW. Stinging insect allergy: natural history and modification with immunotherapy. J Allergy Clin Immunol. 1985; 75: 735-40.
47. Golden DBK, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol. 1981; 67: 370-4.
48. Hauk P, Friedl K, Kaufmehi K, Urbanek R, Forster J. Subsequent insect stings in children with hypersensitivity to Hymenoptera. J Pediair. 1995; 126: 185-90.
49. Graft DF. When to start, when to stop, and what to measure in venom immunotherapy. Issues in Allergy Grand Seminar, AAAI Annual Meeting 1990. J Allergy Clin Immunol. 1991; 88: 409-13.
50. Randolph CC, Reisman RE. Evaluation of decline in serum venom-specific IgE as a criterion for stopping venom immunotherapy. J Allergy Clin Immunol. 1986; 77: 823-7.
51. Reisman RE. Venom immunotherapy. When is it reasonable to stop. J Allergy Clin Immunol. 1991; 87: 618-20.
52. Bousquet J, Knani J, Velasquez G, Menardo JIL, Guilloux IL, Michel FB. Evolution of sensitivity of Hymenoptera venom in 200 allergic patients follow for up to three years. J Allergy Clin Immunol. 1989; 84: 944-50.
53. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: Outcome after five years. J Allergy Clin Immunol. 1996; 97: 579-87.
54. Haugaard L, Norregaard OFH, Dahl R. In-hospital sting challenge in insect venom immunotherapy. J Allergy Clin Immunol. 1991; 87: 699-702.
55. Müller U, Mosbech H. Position paper Immunotherapy with Hymenoptera venoms. Allergy. 1993; 48: 37-46.
56. Ruëff F, Przybilla B, Müller U, Mosbech H. The sting challenge test in hymenoptera venom allergy. Position paper of the sub-committee on insect venom allergy of the EAACI. Allergy. 1996; 51: 216-25.
57. Leung DYM. Atopic dermatitis: the skin window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol. 1995; 96: 302-19.
58. Van Bever HP, Docx M, Stevens W. Food and food additives in severe atopic dermatitis. Allergy 1989; 44: 588-94.
59. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992; 22: 440-6.
60. Panzani RC, Schiavino D, Nucera E et al. Oral hyposensitization to nickel allergy: preliminary clinical results. Int Arch Allergy Immunol. 1995; 107: 251-4.
61. Troost RJJ, Kozel MMA, van Helden-Meeuwsen C et al. Hyposensitization in nickel allergic contact dermatitis: clinical and immunologic monitoring. J Am Acad Dermatol. 1995; 32: 576-83.
62. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997; 99: 744-51.
63. Wuthrich B, Hofer T. Nahrungsmittelallergien. III. Therapie: eliminationsdiet, symptomatische medikamentose prophylaxe und spezifische hyposensibilizierung. Schweiz Med Wochenschr. 1986; 1116: 1401-10.
64. Herrmann D, Henzgen M, Frank E, Rudeschko O, Jäger L. Effect of hyposensitization for tree pollinosis on associated apple allergy. J Invest Allergol Clin Immunol. 1995; 5: 259-67.
65. Frigerio C, Aubry M, Gomez F et al. Desensitization-resistant insulin allergy. Allergy Net. 1996; 52: 238-9.
66. Patterson R. Diagnosis and treatment of drug allergy. J. Allergy Clin Immunol. 1988; 81: 380-4.
67. Borish L, Tamir R, Rosenwasser U. Intravenous desensitization to beta-lactam antibodies. J Allergy Clin Immunol. 1987; 80: 314-9.
68. Szczeklik A. Mechanism of aspirin-induced asthma. Allergy. 1997; 52: 613-9.
69. Pleskow WW Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol. 1982; 69: 11-9.
70. Stevenson DD, Hankammer MA, Mathison DA, Christianson SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: longterm outcomes. J Allergy Clin Immunol. 1996; 98: 751-8.
71. Ebo DG, Stevens WJ, De Clerck LS. Latex anaphylaxis. Acta Clin Belg. 1995; 50: 87-93
72. Ebo DG, Stevens WJ, Bridts CH, De Clerck LS. Human seminal plasma anaphylaxis (HSPA): case report and literature review. Allergy. 1995; 50: 747-50.
73. Boom BW, van Toorenenbergen AW, Nierop G, van der Schroeff JG. A case of seminal fluid allergy successfully treated with immunotherapy in a one-day rush procedure. J Dermatol. 1991; 18: 206-10.